Phase I study of niraparib with radiotherapy for treatment of metastatic and locally advanced invasive carcinoma of the cervix (NIVIX) [0.03%]
Piyush Pathak,Eunji Jo,Susan Hilsenbeck et al.
Piyush Pathak et al.
Introduction: This Phase I study evaluated the safety and tolerability of concurrent niraparib, an oral poly(ADP-ribose) polymerase (PARP) 1/2 inhibitor, with definitive radiotherapy in women with locally advanced or plat...
Case Report: Immune checkpoint inhibitor-triggered anti-Ma2 paraneoplastic encephalitis in sarcomatoid pleural mesothelioma: a fatal case [0.03%]
Ilker Nihat Okten,Tuba Baydaş
Ilker Nihat Okten
Background: Neurological immune-related adverse events (N-irAEs) represent rare but potentially fatal complications of immune checkpoint inhibitor (ICI) therapy. Among these, encephalitis associated with paraneoplatic neu...
Laura Boeckaerts,Tania Løve Aaes,Evi Scheirlinckx et al.
Laura Boeckaerts et al.
Introduction: Colorectal cancer (CRC) is the thirdmost common cancer and a leading cause of cancer deaths worldwide, with over 1.9 million cases diagnosed in 2022. Due to poor response to classical cancer treatments, CRC ...
Hsin-Yun Lin,Sokchea Khou,Evan Lind et al.
Hsin-Yun Lin et al.
Introduction: Tousled-like kinase 2 (TLK2) is a serine/threonine kinase that plays a role in DNA replication, chromatin remodeling, and DNA damage response. TLK2 has been implicated in the pathogenesis of various types of...
A dynamic nomogram for predicting axillary pathological complete response and its prognostic value in HER2-positive breast cancer [0.03%]
Xiaona Liu,Xiaoqian Li,Pan Liu et al.
Xiaona Liu et al.
Background: Accurate preoperative prediction of axillary pathological complete response (apCR) following neoadjuvant therapy (NAT) is crucial for de-escalating axillary surgery in breast cancer (BC) patients. This study a...
Efficacy of traditional Chinese medicine combined with chemotherapy for gastric cancer and precancerous gastric lesions: a systematic review and meta-analysis [0.03%]
Xiao Liang,Liu Yang,Shuaiqi Yuan et al.
Xiao Liang et al.
Background: Despite the advancements in therapeutic regimens, gastric cancer is still among the most concerning cancer-related public health problems. In previous literature, Traditional Chinese Medicine (TCM) proved to b...
Comprehensive toxicity profile of the 4AC-4THP neoadjuvant regimen in HER2-positive breast cancer: a multicenter real-world study in Vietnam [0.03%]
Anh Dinh Tran,Le Huy Trinh,Tuan Anh Pham
Anh Dinh Tran
Background: The 4AC-4THP regimen-comprising doxorubicin and cyclophosphamide followed by docetaxel, trastuzumab, and pertuzumab-has been widely adopted as neoadjuvant treatment for HER2-positive breast cancer. While effic...
Correction: Part II: consensus statements and expert recommendations for BRCA-associated breast cancer in the Asia-Pacific region: clinical management [0.03%]
Yeon Hee Park,Soo Chin Lee,Christian F Singer et al.
Yeon Hee Park et al.
[This corrects the article DOI: 10.3389/fonc.2025.1507840.]. Keywords: BRCA germline pathogenic variants; HE...
Published Erratum
Frontiers in oncology. 2026 Mar 9:16:1807980. DOI:10.3389/fonc.2026.1807980 2026
Zhi-Xin Xie,Ai-Ming Yang,Qiang Wang
Zhi-Xin Xie
Carcinoembryonic antigen is a glycoprotein often associated with colorectal carcinoma but can also increase in other malignancies. We reported a rare case of prostate mucinous adenocarcinoma in a 69-year-old male with elevated carcinoembryo...
Case Report: Lorlatinib for the treatment of ALK-rearranged poorly differentiated thyroid carcinoma after progression to prior ALK-specific tyrosine-kinase inhibitor [0.03%]
Jesús Yaringaño,Jorge Hernando,Alejandro García-Álvarez et al.
Jesús Yaringaño et al.
ALK rearrangements are rare but actionable oncogenic drivers in thyroid cancer, particularly in aggressive histologies such as poorly differentiated thyroid carcinoma (PDTC), and evidence supporting sequential ALK inhibition in this setting...